OTLK

Outlook Therapeutics Inc

0.6526

Sep 03 • 2:23 PM ET +0.0263 (4.20%)

Healthcare Biotechnology USA Micro NASD

Peers: XLO GLSI INDP TARA PALI PRLD RNTX RZLT TELO RADX

Index	-
Market Cap	158.87M
Enterprise Value	166.06M
Income	-43.44M
Sales	1.51M
Book/sh	-0.06
Cash/sh	0.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 14, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	105.21
P/B	-
P/C	14.13
P/FCF	-
EV/EBITDA	-
EV/Sales	109.98
Quick Ratio	0.63
Current Ratio	0.81
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.09
EPS next Y	-0.19
EPS next Q	-0.07
EPS this Y	72.35%
EPS next Y	61.11%
EPS next 5Y	-
EPS past 3/5Y	33.96% 33.18%
Sales past 3/5Y	- -
EPS Y/Y TTM	86.28%
Sales Y/Y TTM	-
EPS Q/Q	90.10%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-75.00% -99.07%

Insider Own	12.68%
Insider Trans	61.46%
Inst Own	18.46%
Inst Trans	7.18%
ROA	-125.04%
ROE	-
ROIC	-
Gross Margin	63.07%
Oper. Margin	-4824.52%
Profit Margin	-2885.82%
SMA20	-13.70%
SMA50	-41.61%
SMA200	-25.01%
Trades

Shs Outstand	243.45M
Shs Float	212.58M
Short Float	9.36%
Short Ratio	1.13
Short Interest	19.90M
52W High	2.54 -74.28%
52W Low	0.16 305.09%
Volatility	5.72% 10.28%
ATR (14)	0.09
RSI (14)	36.38
Beta	0.66
Rel Volume	0.42
Avg Volume	17.63M
Volume	5,654,563

Perf Week	1.79%
Perf Month	-36.64%
Perf Quarter	-17.89%
Perf Half Y	51.13%
Perf YTD	-58.70%
Perf Year	-26.67%
Perf 3Y	-85.57%
Perf 5Y	-98.74%
Perf 10Y	-99.91%
Recom	1.50
Target Price	4.90
Prev Close	0.63
Price	0.65
Change %	4.20%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-26	Upgrade	BTIG Research	Neutral → Buy	$4
May-18-26	Downgrade	BTIG Research	Buy → Neutral
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy	$50
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy	$3
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight	$5
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10

Show Previous Ratings

Aug-27-26 04:05PM	Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA (GlobeNewswire)
09:01AM	Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire)
Aug-14-26 08:30AM	Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary (Moby) -14.90%
07:15AM	Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA (GlobeNewswire)
Aug-13-26 06:31AM	Why Did OTLK Stock Crash In Pre-Market Today? (Stocktwits) -19.20%
09:45PM	Loading…
Aug-12-26 09:45PM	Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Aug-06-26 08:45AM	Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 (GlobeNewswire) -5.58%
Jul-27-26 01:45PM	Outlook Therapeutics Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG (Stocktwits) -24.20%
07:13AM	Outlook Therapeutics wins FDA approval for Lytenava in wet AMD (Pharmaceutical Technology)
07:12AM	Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD (InvestorsHub)
07:00AM	FDA scientists question Capricor data; Legend CEO steps down (BioPharma Dive)
02:47AM	OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug Analysts See Nearly 300% Upside (Stocktwits)
Jul-24-26 08:30PM	FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions (Stocktwits) +6.44%
07:47PM	OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab (Stocktwits)
02:40PM	Loading…
02:40PM	Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD (GlobeNewswire)
Jul-23-26 01:00PM	OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy Retail Says Favorable Verdict Could Cause A Big Boom (Stocktwits)
Jun-16-26 01:47PM	OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision (Stocktwits) +35.34%
08:02AM	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a Treatment for Wet AMD (GlobeNewswire)
Jun-01-26 01:05PM	OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal (Stocktwits) +15.48%
08:46AM	Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-28-26 04:00PM	Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +26.39%
01:38PM	OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record (Stocktwits)
May-27-26 01:10AM	Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday (Stocktwits) +46.30%
May-26-26 09:08AM	OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone Whats Behind This Massive Rally? (Stocktwits) +29.14%
07:00AM	Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-15-26 04:05PM	Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-23-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) +9.83%
Apr-22-26 08:30AM	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.14%
Apr-21-26 09:05AM	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire) -13.68%
08:50AM	Loading…
Apr-07-26 08:50AM	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA (GlobeNewswire) +6.18%
Mar-25-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire)
Mar-24-26 07:00AM	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -38.06%
Mar-23-26 05:30PM	Outlook Therapeutics Announces Proposed Public Offering (GlobeNewswire) -8.91%
Mar-16-26 08:05AM	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note (GlobeNewswire) -10.69%
Mar-05-26 04:15PM	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
Feb-19-26 09:00AM	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland (GlobeNewswire) +6.10%
Feb-17-26 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.82%
08:05AM	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-11-26 08:45AM	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter (GlobeNewswire) +11.52%
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks) +11.43%
Jan-06-26 08:35AM	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development (GlobeNewswire)
Jan-02-26 07:29AM	Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks (Investing.com) -58.23%
Jan-01-26 04:35PM	FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form (TipRanks)
Dec-31-25 04:15PM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire) -15.28% -58.23%
Dec-26-25 05:00PM	Outlook Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +8.79%
Dec-19-25 09:30AM	Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 (GlobeNewswire)
Dec-16-25 11:39AM	Micron Dominates Barchart's Top 100 with Killer VolumeYour Buy Signal? (Barchart) +13.82%
Nov-24-25 09:05AM	Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:30AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +14.84%
Nov-03-25 08:35AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 (GlobeNewswire)
Sep-29-25 08:45AM	Outlook Therapeutics Provides Update on Type A Meeting with FDA (GlobeNewswire) +9.27%
Sep-03-25 08:35AM	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:35AM	Outlook Therapeutics Requests Type A Meeting with FDA (GlobeNewswire)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks) -21.91%
09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-28-25 11:15AM	FDA Rejects Outlook Therapeutics Eye Drug For Second Time (Benzinga) -54.11%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:30AM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.38%
Aug-14-25 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.08%
08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Jul-30-25 05:50AM	New Strong Buy Stocks for July 30th (Zacks)
Jul-24-25 09:00AM	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Jul-22-25 08:45AM	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-01-25 08:05AM	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer (GlobeNewswire)
Jun-18-25 09:05AM	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event (GlobeNewswire)
Jun-11-25 05:06AM	Outlooks wet AMD treatment accepted by SMC for NHS Scotland (Pharmaceutical Technology)
Jun-10-25 08:05AM	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
Jun-02-25 07:00AM	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD (GlobeNewswire)
May-23-25 06:30AM	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering (GlobeNewswire)
May-22-25 04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
May-15-25 04:01PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:45AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Mar-20-25 05:24PM	Outlook Therapeutics files to sell 21.72M shares of common stock for holders (SeekingAlpha)
Feb-28-25 08:05AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire) +8.70%
Feb-19-25 09:00AM	Outlook Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-14-25 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Feb-04-25 09:05AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jan-31-25 08:05AM	Outlook Therapeutics Appoints Faisal G. Sukhtian as Chairman of the Board of Directors (GlobeNewswire)
Jan-23-25 09:05AM	Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Jan-22-25 09:05AM	Outlook Therapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -8.93%
Jan-16-25 12:09PM	Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug (Benzinga)
06:00AM	Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Jan-08-25 09:15AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire) -5.22%
Dec-30-24 07:45AM	Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss (GuruFocus.com) -7.46%
Dec-28-24 10:50PM	Outlook Therapeutics Reports 2024 Financial Results (TipRanks)
08:10AM	Outlook Therapeutics provides ONS-5010/LYTENAVA update (TipRanks)
Dec-27-24 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) +18.24%
Dec-13-24 04:30PM	Outlook Therapeutics Streamlines Operations (GlobeNewswire)
Dec-04-24 08:05AM	Outlook Therapeutics Announces NICE Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) -8.03%
Dec-03-24 04:30PM	Outlook Therapeutics Announces Executive Leadership Transition (GlobeNewswire) -11.08%
Nov-30-24 05:50AM	Outlook Therapeutics price target lowered to $9 from $50 at BTIG (TipRanks)
Nov-27-24 11:08AM	Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial (Pharmaceutical Technology) -65.24%
11:07AM	Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial (Clinical Trials Arena)
09:27AM	Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? (Benzinga)
06:50AM	Outlook Therapeutics Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial (GlobeNewswire)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

PresidentMr. Robert Charles Jahr

Senior Vice President of Licensing and M&AMr. Joel Prieve

Senior Vice President of Medical AffairsDr. Surendra Sharma M.D.

Senior Vice President of Clinical Development & Regulatory AffairsDr. Jennifer M. Kissner Ph.D.

Senior VPMr. Jedd Comiskey

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sukhtian Ghiath M.	Director	Aug 12 '26	Buy	0.99	2,525,252	2,499,999	24,617,320	Aug 14 07:52 PM
Sukhtian Faisal Ghiath	Director	Jul 29 '26	Buy	1.05	95,398	99,996	220,972	Jul 29 03:19 PM
Haddadin Yezan Munther	Director	Jun 02 '26	Buy	0.83	29,000	24,145	66,167	Jun 03 06:03 PM
Sukhtian Ghiath M.	Director	May 28 '26	Buy	0.59	8,539,709	5,000,000	22,092,068	Jun 01 09:30 PM
Sukhtian Faisal Ghiath	Director	May 27 '26	Buy	0.41	122,174	50,006	125,574	May 27 03:29 PM
Haddadin Yezan Munther	Director	May 26 '26	Buy	0.44	34,000	14,960	37,167	May 27 03:24 PM
THURMAN RANDY H	Director	May 26 '26	Buy	0.43	5,000	2,145	5,593	May 27 03:20 PM
HILZINGER KURT J	Director	May 26 '26	Buy	0.44	400,000	176,520	423,655	May 27 03:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your Finviz experience